Second, targeting XRN2 can also enhance anti-GBM therapies, especially radiation, which is a first-line anti-GBM therapy [5], as well as PARP1 inhibitors, which are currently used in clinical trials for GBM therapy [34]. The gene discussed is PARP1; the disease is glioblastoma.